On Monday, June 8, 2026, UK-based consumer healthcare titan Haleon plc announced a massive ₹2,000 crore (£175 million) capital allocation to establish its first-ever owned manufacturing plant in India and South Asia.
This greenfield project marks a major operational pivot for the company. Historically, Haleon has relied entirely on third-party contract manufacturing organizations (CMOs) to produce its goods for the Indian subcontinent.
Project Blueprint: The Pithampur Smart Plant
The upcoming factory is engineered around Haleon’s “global advance blueprint,” prioritizing full-scale automation and high-efficiency product routing.
- Location: Spanning 40 acres within the Smart Industrial Park in Pithampur, Madhya Pradesh. The central location was chosen to minimize domestic logistics timelines and tap into the region’s technical engineering colleges.
- Operational Horizon: Scheduled to be fully operational by 2029–30.
- Core Production Focus: Primarily dedicated to high-volume output for Haleon’s flagship oral health franchise, specifically Sensodyne and Parodontax.
- Socio-Economic Footprint: Projected to generate 500 direct technical jobs alongside extensive indirect supply-chain employment. The company has also outlined an inclusive hiring target of maintaining at least 30% women employees on the factory floor.
The Corporate Architecture: From GSK/Pfizer to Independent Giant
Understanding Haleon’s corporate genealogy explains the scale of this investment:
[GSK Consumer Healthcare] + [Pfizer Consumer Health]
│
▼ (Merged Joint Venture)
[GSK-Pfizer Consumer JV]
│
▼ (Spun off & Listed on NYSE/LSE in 2022)
[HALEON]
($14.55 Billion Global Revenue Base)
While brands like Horlicks and Boost stayed with Hindustan Unilever (HUL) following a 2020 domestic merger, Haleon retained control over a high-margin over-the-counter (OTC) and wellness portfolio. Today, its presence in India spans four core categories:
| Segment | Leading Sub-Brands |
| Oral Health | Sensodyne, Parodontax |
| Digestive Health | Eno |
| Pain & Respiratory | Crocin, Iodex, Otrivin |
| Vitamins & Supplements | Centrum |
Strategic Rationale: Driving the “Win as One” Strategy
According to Global CEO Brian McNamara and India MD Kedar Lele, localizing production lines serves three distinct market demands:
- Feeding the Rural Last-Mile Push: India’s consumer health sector is undergoing a massive structural shift toward preventive daily self-care, with the domestic market projected to surpass £23 billion (~₹2.4 lakh crore) by 2030. To capture rural demographics, Haleon is aggressively scaling down-market via lower-cost, small-format entries—such as its ₹20 Sensodyne pack—targeting a footprint of 3 million retail outlets.
- De-risking the Supply Chain: Moving production from third-party partners to an in-house, automated facility protects Haleon from supply shocks, tightens margin controls, and guarantees strict compliance with localized formulation requirements.
- An Export Springboard for Asia: While the plant will serve 300 million consumers in India alone, Pithampur is explicitly designated to act as a primary export gateway to feed high-demand markets across wider Asia.
“India is a top-10 market for Haleon globally and a bright spot amid global headwinds. This investment strengthens our local manufacturing footprint and expands our reach in one of the world’s fastest-growing consumer health markets.” — Brian McNamara, Global CEO, Haleon.